Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Dapagliflozin
38%
Biological Marker
23%
Galectin 3
17%
Congestive Heart Failure
17%
Heart Failure with Reduced Ejection Fraction
13%
Cardiomyopathy
13%
Heart Failure with Preserved Ejection Fraction
11%
Placebo
11%
Disease
10%
Heart Infarction
9%
Cardiovascular Disease
8%
Adverse Outcome
8%
Heart Ventricle Remodeling
8%
Phospholamban
8%
Fibrosis
8%
Brain Natriuretic Peptide
7%
Malignant Neoplasm
7%
Natriuretic Factor
6%
Heart Muscle Fibrosis
6%
Troponin T
6%
Mouse
6%
All Cause Mortality
6%
Terminal Illness
5%
Renin
5%
Non Insulin Dependent Diabetes Mellitus
5%
Atrial Fibrillation
5%
Medicine and Dentistry
Heart Failure
72%
Ejection Fraction
21%
Dapagliflozin
19%
Biological Marker
16%
Cardiology
15%
Congestive Heart Failure
14%
Cardiovascular System
14%
Heart Failure with Preserved Ejection Fraction
12%
Heart Failure with Reduced Ejection Fraction
11%
Cardiovascular Disease
11%
Malignant Neoplasm
11%
Cardiomyopathy
10%
Hazard Ratio
10%
Heart Left Ventricle Ejection Fraction
9%
Phospholamban
8%
Heart Function
7%
Atrial Fibrillation
7%
Oncology
7%
Meta-Analysis
6%
Diseases
6%
Natriuretic Factor
6%
Diabetes
6%
Myocardial Infarction
5%
Maturity Onset Diabetes of the Young
5%
Placebo
5%
Terminal Illness
5%
Biochemistry, Genetics and Molecular Biology
Galectin-3
11%
Heart Ejection Fraction
10%
Phospholamban
9%
Natriuretic Peptide
9%
Cardiac Muscle Cell
7%
N-Terminus
7%
Population
6%
All Cause Mortality
6%
Troponin T
5%
